Baidu
map

J Clin Oncol:霍奇金淋巴瘤患者5年内的健康相关生命质量(HRQoL)

2020-06-24 MedSci原创 MedSci原创

健康相关生命质量(HRQoL)是指在疾病、意外损伤及医疗干预的影响下,测定与个人生活事件相联系的主观健康状态和个体满意度。

健康相关生命质量(HRQoL)是指在疾病、意外损伤及医疗干预的影响下,测定与个人生活事件相联系的主观健康状态和个体满意度。健康状态和主观满意度构成了其主要内容,更多的是采用自我评价,常用的指标是主观指标,建立的基础是在个体的一定的文化价值体系下,故具有文化依赖性。

因为很少进行大型的与健康相关生命质量(HRQoL)的纵向研究,在霍奇金淋巴瘤(HL)确诊和治疗后HRQoL的许多的重要细节仍然未知。因此,Kreissl等人分析了从确诊到存活5年的所有阶段的HL患者的综合评估的HRQoL。

本研究纳入了来自德国霍奇金研究小组HD13、HD14和HD15试验中于18-60岁期间确诊的HL患者。通过欧洲研究和治疗癌症生活质量问卷C30的所有功能和症状量表(包括与参考值的偏差)分析受试者的HRQoL。使用多元回归和重复测量分析不同疾病、患者和治疗特征的影响,以及与HRQoL得分的相关性。

共分析了4215位在治疗后5年内有HRQoL评估的患者。确诊时高肿瘤负荷与多个HRQoL模块的基础评分受损有关。在存活期间,认知、情感、角色和社交功能以及疲劳、呼吸困难、睡眠和财务问题均受到了持续的严重影响。从第二年开始,参考值的平均偏差范围在12-29分之间时,10分是临床相关性的常用阈值。在3个试验中,治疗后2年和5年的HRQoL域均受到基线评分和年龄的显著影响,但不受随机治疗的影响。疲劳与其他症状和程度的关系最密切。

本研究结果表明,很多HL幸存者持续存在不同程度的HRQoL缺陷,这些缺陷在很大程度上与所接受的化疗无关。该分析强调了这些年轻的霍奇金淋巴瘤幸存者对癌症经历的社会心理不良影响的高度未满足的医疗需求。

原始出处:

Stefanie Kreissl,et al. Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group. Journal of Clinical Oncology. June,2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1699494, encodeId=e0b216994942f, content=<a href='/topic/show?id=8ce7149e209' target=_blank style='color:#2F92EE;'>#QOL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14972, encryptionId=8ce7149e209, topicName=QOL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b029929630, createdName=lancelotzzl, createdTime=Sat Jan 02 12:39:05 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865858, encodeId=f4631865858f7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jan 09 10:39:05 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539259, encodeId=d59a153925922, content=<a href='/topic/show?id=294e911680' target=_blank style='color:#2F92EE;'>#HRQOL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9116, encryptionId=294e911680, topicName=HRQOL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2613125915, createdName=pyaili, createdTime=Fri Jun 26 08:39:05 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038059, encodeId=2a85103805950, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Jun 24 20:39:05 CST 2020, time=2020-06-24, status=1, ipAttribution=)]
    2021-01-02 lancelotzzl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1699494, encodeId=e0b216994942f, content=<a href='/topic/show?id=8ce7149e209' target=_blank style='color:#2F92EE;'>#QOL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14972, encryptionId=8ce7149e209, topicName=QOL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b029929630, createdName=lancelotzzl, createdTime=Sat Jan 02 12:39:05 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865858, encodeId=f4631865858f7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jan 09 10:39:05 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539259, encodeId=d59a153925922, content=<a href='/topic/show?id=294e911680' target=_blank style='color:#2F92EE;'>#HRQOL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9116, encryptionId=294e911680, topicName=HRQOL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2613125915, createdName=pyaili, createdTime=Fri Jun 26 08:39:05 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038059, encodeId=2a85103805950, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Jun 24 20:39:05 CST 2020, time=2020-06-24, status=1, ipAttribution=)]
    2021-01-09 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1699494, encodeId=e0b216994942f, content=<a href='/topic/show?id=8ce7149e209' target=_blank style='color:#2F92EE;'>#QOL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14972, encryptionId=8ce7149e209, topicName=QOL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b029929630, createdName=lancelotzzl, createdTime=Sat Jan 02 12:39:05 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865858, encodeId=f4631865858f7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jan 09 10:39:05 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539259, encodeId=d59a153925922, content=<a href='/topic/show?id=294e911680' target=_blank style='color:#2F92EE;'>#HRQOL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9116, encryptionId=294e911680, topicName=HRQOL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2613125915, createdName=pyaili, createdTime=Fri Jun 26 08:39:05 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038059, encodeId=2a85103805950, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Jun 24 20:39:05 CST 2020, time=2020-06-24, status=1, ipAttribution=)]
    2020-06-26 pyaili
  4. [GetPortalCommentsPageByObjectIdResponse(id=1699494, encodeId=e0b216994942f, content=<a href='/topic/show?id=8ce7149e209' target=_blank style='color:#2F92EE;'>#QOL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14972, encryptionId=8ce7149e209, topicName=QOL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b029929630, createdName=lancelotzzl, createdTime=Sat Jan 02 12:39:05 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865858, encodeId=f4631865858f7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jan 09 10:39:05 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539259, encodeId=d59a153925922, content=<a href='/topic/show?id=294e911680' target=_blank style='color:#2F92EE;'>#HRQOL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9116, encryptionId=294e911680, topicName=HRQOL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2613125915, createdName=pyaili, createdTime=Fri Jun 26 08:39:05 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038059, encodeId=2a85103805950, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Jun 24 20:39:05 CST 2020, time=2020-06-24, status=1, ipAttribution=)]
    2020-06-24 anti-cancer

    谢谢梅斯分享这么多精彩信息

    0

相关资讯

男性,反复咳嗽,乏力,请诊断!

男性,反复咳嗽,乏力,请诊断!

Lancet Haematol:产前治疗or产后治疗,霍奇金淋巴瘤孕妇患者及新生儿的生存预后有什么不同?

目前关于妊娠期间诊断为霍奇金淋巴瘤的患者及其新生儿预后结局的研究不足,对霍奇金淋巴瘤产前管理的相关报道也不多。近日,发表在Lancet Haematology的一项回顾性队列研究探讨了妊娠期间诊断为霍奇金淋巴瘤患者产前治疗或产后治疗对孕产妇及其新生儿生存预后的影响。

Lancet oncol:派姆单抗治疗儿科各类肿瘤的疗效

派姆单抗已被批准用于治疗成人晚期癌症,但尚无派姆单抗用于儿科癌症患者的疗效和安全性的相关信息。现研究人员开展一项1-2期开放性研究,以明确派姆单抗用于晚期小儿癌症推荐的2期剂量、安全性和抗肿瘤活性。从多个国家的30家医院招募6-17岁的黑色素瘤或PD-L1阳性的复发性或难治性实体肿瘤或淋巴瘤患儿,要求Lansky Play/Karnofsky表现状态评分≥50,予以派姆单抗 静脉注射,初始剂量2m

JCO:PD-L1用于新诊断的晚期经典霍奇金淋巴瘤

Nivolumab用于新诊断的晚期经典霍奇金淋巴瘤:II期CheckMate205研究中的安全性和有效性

JSH实践指南:血液恶性肿瘤—Ⅱ淋巴瘤:霍奇金淋巴瘤

2018年日本血液学会(JSH)血液恶性肿瘤—淋巴瘤指南,本文为霍奇金淋巴瘤管理指南,主要涉及各阶段霍奇金淋巴瘤的管理等内容。

喜讯!中国**靶向CD30的抗体药物偶联物ADCETRIS(brentuximab vedotin)获得批准

武田中国今日宣布,靶向CD30的ADCETRIS(brentuximab vedotin)已获得中国国家药品监督管理局(NMPA)的正式批准。

Baidu
map
Baidu
map
Baidu
map